Authors

Latest:

Dr. Matsen on the Effects of Decreased Breast Cancer Screening in the COVID-19 Era

Cindy B. Matsen, MD, discusses the potential effects of the decrease in screening for patients with breast cancer during the coronavirus disease 2019 pandemic.

Asal Rahimi, MD, MS

Latest:

Dr Rahimi on Escalating Preoperative, Single-Fraction Ablative Radiation in HR-Positive Breast Cancer

Asal Rahimi, MD, MS, discusses initial efficacy results from the expanded cohort of a phase 1 dose-escalation study (NCT04040569) evaluating pre-operative, single fraction stereotactic ablative radiation in early-stage, hormone receptor–positive breast cancer.

Christine Duncan, MD, Dana-Farber Cancer Institute

Latest:

Narsoplimab: The Phase 2 Trial

Samer Khaled, MD reviews the design, results, and practical implications of the pivotal phase 2 trial of narsoplimab, a MASP-2 targeted monoclonal antibody under investigation for the treatment of thrombotic microangiopathy associated with hematopoietic stem cell transplantation.

Kimberly Halla, NP

Latest:

Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer

Closing their discussion, the panel shares advice for new nurse practitioners caring for patients who have endometrial cancer.

Luis E Raez, MD, FASCO, FACP

Luis E. Raez, MD, FACP, FASCO, is the medical director of Memorial Cancer Institute, oncology research director of Memorial Health Care System, and director of the Thoracic Oncology Program at the Florida Society of Clinical Oncology. He is also a clinical associate professor of medicine at Florida International University and a visiting professor of medicine at Cayetano Heredia University in Peru.

Latest:

Exploring the Latest in EGFR-Mutant Lung Cancer With Drs Ramalingam and Raez

Luis E. Raez, MD, and Suresh S. Ramalingam, MD, FACP, FASCO, sit down with Chandler Park, MD, FACP, and Eric K. Singhi, MD, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Katherine L. Nathanson, MD

Katherine L. Nathanson, MD, serves as director of the Penn Medicine Center for Genomic Medicine and deputy director of Abramson Cancer Center. She is also principal investigator and Pearl Basser Professor of BRCA-related Research at Perelman School of Medicine, of the University of Pennsylvania.

Latest:

Dr Nathanson on the Role of Reversion Mutations in PARP Inhibitor Resistance in Breast Cancer

Katherine L. Nathanson, MD, discusses the impact of reversion mutations on resistance to PARP inhibitors across various DNA damage repair genes.

Joseph Jacob, MD, MCR

Joseph Jacob, MD, MSc, Director of Urologic Oncology,

Latest:

FDA Approval Insights: Gemcitabine Intravesical System for NMIBC: With Joseph Jacob, MD, MCR

Dr Jacob discusses the significance of the FDA approval of the gemcitabine intravesical system for BCG-unresponsive non–muscle-invasive bladder cancer.

Alyson B. Moadel-Robblee, PhD

Latest:

Evolving Psychosocial Care Models Step Forward as the Next Targeted Cancer Therapy

During this search for a breast cancer support system, my mother also investigated complementary therapies that peers had used to help cope with their fears, adverse effects, and feelings of helplessness.

Robert Emmons, MD, FACP

Latest:

Catching Up on the Latest Data in CLL and Lymphoma With Drs Emmons, Brody, and Pinilla

Robert Emmons, MD, FACP, Joshua Brody, MD, and Javier Pinilla, MD, PhD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in chronic lymphocytic leukemia and lymphoma presented during the 2025 ASH Annual Meeting & Exposition.

Cindy Medina Pabon, MD

Latest:

Dr Pabon on the FDA Approval of Zolbetuximab for CLDN18.2+ Gastric/GEJ Adenocarcinoma

Cindy Medina Pabon, MD, discusses the clinical relevance of the FDA approval of zolbetuximab for CLDN18.2-positive gastric or GEJ adenocarcinoma.

Mats Jerkeman, MD

Mats Jerkeman, MD is a Professor of Oncology, Lund University.

Latest:

Dr Jerkeman on Symptom Identification for Earlier MCL Diagnosis

Mats Jerkeman, MD, discusses essential symptoms of MCL warranting referral for earlier diagnosis.

Tapan M. Kadia, MD

Latest:

Dr Kadia on Targeting the IRAK4 Pathway in AML

Tapan M. Kadia, MD, discusses targeting the IRAK4 pathway in patients with acute myeloid leukemia and highlights the importance of utilizing targeted therapies in the treatment of patients with hematologic malignancies.

Laura Farrington, DO

Latest:

Women in Oncology: Lessons to Tell Up-and-Coming Female Oncologists

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, provide advice to female oncologists who are just starting out their careers.

Mariya Rozenblit, MD

Latest:

Dr Rozenblit on Pembrolizumab Outcomes by TMB Status in HR+ Metastatic Breast Cancer

Mariya Rozenblit, MD, discusses how genomic alterations and TMB influence the efficacy of immune checkpoint inhibitors in HR+ metastatic breast cancer.

Jay Moon Lee, MD

Latest:

Dr. Lee on the Current State of Molecular Testing in Early-Stage NSCLC

Jay Moon Lee, MD, discusses the current state of molecular testing in early-stage non–small cell lung cancer.

Angela J. Keleher, MD

Latest:

Breast Nerve Preservation and Grafting: How Surgeons Can Help Mitigate Sensation Loss

More surgeons are having in-depth conversations with their patients with breast cancer and prophylactic patients about the fact that nerves will have to be cut during their mastectomy, how that will impact sensation and quality of life, and how surgeon collaboration and breast neurotization can help restore sensation.

Nicole Odzer

Latest:

Odzer on ERBB2 Copy Number Ratio as a Predictive Biomarker in HER2+ Breast Cancer

Nicole Odzer discusses the utility of ERBB2 copy number ratio as a predictive biomarker in HER2+ breast cancer.

Gail J. Roboz, MD

Latest:

Women in Oncology: Prioritization and Passionate Legacies

Selina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.

Nicoletta Colombo, MD, PhD

Latest:

Endometrial Cancer Today: Defining the Persistent Unmet Needs in Advanced and Recurrent Disease

Panelists discuss how advanced/recurrent endometrial cancer has remained a high unmet need due to years of minimal survival gains with carboplatin/paclitaxel until immunotherapy began shifting outcomes.

Olalekan O. Oluwole, MBBS, MD

Latest:

Dr Oluwole on the Use of CAR T-Cell Therapy in Autoimmune Disorders

Olalekan O. Oluwole, MBBS, MD, discusses the feasibility of using CAR T-cell therapy in patients with nonhematologic autoimmune disorders.